亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药

已收盘 07-03 16:08:15

36.880

+1.980

+5.67%

最高37.000	最低35.620	成交量343.59万
今开36.020	昨收34.900	日振幅3.95%
总市值137.93亿	流通市值137.93亿	总股本3.74亿
成交额1.25亿	换手率0.92%	流通股本3.74亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药","latestPrice":36.88,"timestamp":1783066095009,"preClose":34.9,"halted":0,"volume":3435864,"delay":0,"changeRate":0.05673352435530098,"floatShares":374000000,"shares":374000000,"eps":-4.033702727714774,"marketStatus":"已收盘","change":1.98,"latestTime":"07-03 16:08:15","open":36.02,"high":37,"low":35.62,"amount":125267577,"amplitude":0.039542,"askPrice":36.88,"askSize":7400,"bidPrice":36.82,"bidSize":8700,"shortable":3,"etf":0,"ttmEps":-4.260237322165231,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":5,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":34.9,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":1.240244,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2647858376","title":"亚盛医药(06855)根据2021年受限制股份单位计划授出44.07万份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2647858376","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647858376?lang=zh_cn&edition=full","pubTime":"2026-06-30 08:53","pubTimestamp":1782780809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 发布公告，截至本公告日期，已根据2021年受限制股份单位计划向2021年受限制股份单位计划的453名获选人士授出44.07万份受限制股份单位，相当于44.07万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01530","LU1328277881.USD","IE00B5MMRT66.SGD","LU0348735423.USD","09995","LU0348783233.USD","LU0540923850.HKD","LU2476274308.USD","LU0417516902.SGD","LU0348825331.USD","LU1720050803.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU0348827113.USD","LU1969619763.USD","LU1993786604.SGD","LU0140636845.USD","LU0634319403.HKD","06855","LU2476274720.SGD","09926","01093","159992","02157","LU1961090484.USD","LU1008478684.HKD","BK1583","LU1226287792.SGD","LU0067412154.USD","IE00B543WZ88.USD","LU0072913022.USD","LU0348767384.USD","02637","BK1141","LU1226288253.USD","LU0348784397.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","02162","BK1574","LU0417516571.SGD","LU1960683339.HKD","06978","09969","LU0326950275.SGD","LU0880133367.SGD","02228","LU0315179316.USD","LU0348766576.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00BPRC5H50.USD","LU0417516571.SGD","LU1720050803.USD","BK4531","SG9999002463.SGD","06160","HK0000320223.HKD","LU2488822045.USD","06855","01548","02162","LU0456846285.SGD","09688","BK1141","06978","159992","BK1589","HK0000306685.HKD","LU0588546209.SGD","ZLAB","LU0348827113.USD","HK0000306701.USD","LU0307460666.USD","LU0979878070.USD","LU0326950275.SGD","LU0516422366.SGD","LU0516422952.EUR","LU0561508036.HKD","LU2476274308.USD","BK4526","LU1969619763.USD","09926","LU0516423091.SGD","LU0348784397.USD","BK1587","LU1303224171.USD","BK1521","LU2328871848.SGD","LU0516423174.USD","LU1719994722.HKD","LU1961090484.USD","LU0140636845.USD","LU2045819591.USD","LU1794554557.SGD","BK1588","BK1583","02359","02269","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228118","title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228118","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643228118?lang=zh_cn&edition=full","pubTime":"2026-06-15 07:29","pubTimestamp":1781479754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药 公布，公司核心产品的17项临床进展已在2026年欧洲血液学协会年会上精彩亮相，其中包括8项壁报展示。2026年欧洲血液学协会 年会于2026年6月11日至2026年6月14日在瑞典斯德哥尔摩举办。利沙托克拉在髓系肿瘤的真实世界数据也为其临床价值提供了强有力的佐证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药(06855)在2026年欧洲血液学协会(EHA)年会公布多项临床进展","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","06855","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642287999","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划目的购买11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642287999","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642287999?lang=zh_cn&edition=full","pubTime":"2026-06-11 21:31","pubTimestamp":1781184682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月11日，受托人就2022年受限制股份单位计划目的于场内购买合共11万股现有股份以在归属后满足受限制股份单位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK4139","BK1161","BK1574","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642426730","title":"亚盛医药(06855)：受托人就2022年受限制股份单位计划购买19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642426730","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642426730?lang=zh_cn&edition=full","pubTime":"2026-06-10 20:54","pubTimestamp":1781096082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药(06855)发布公告，于2026年6月10日，受托人就2022年受限制股份单位计划目的于场内购买合共19万股现有股份以在归属后满足受限制股份单位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AAPG","BK1574","BK4139","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169106576","title":"亚盛医药-B更新5月股份变动月报表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1169106576","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169106576?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:21","pubTimestamp":1780575698,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年6月4日发布截至2026年5月31日止的股份变动月报表。公告显示，公司法定股本未发生变化，仍为500,000,000股普通股，面值每股US$0.0001，注册股本总额为US$50,000。公司当月库存股数量保持为0股。截至5月底，公司已发行股本总数增至373,555,768股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律法规。上述月报表由公司秘书梁凯恩签字。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640937177","title":"国泰海通证券：首予亚盛医药(06855)“增持”评级 目标价59.09港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2640937177","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640937177?lang=zh_cn&edition=full","pubTime":"2026-06-01 16:58","pubTimestamp":1780304322,"startTime":"0","endTime":"0","summary":"2025年，公司商业化成果显著，实现总收益5.74亿元，不考虑武田付款同比增长90%，其中，奥雷巴替尼实现收入4.35亿元，利沙托克拉实现7085万元，合计5.06亿元。2025年末现金余额为24.7亿元，现金储备稳健，可以支撑到2027年。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260601/20260601165411_97234.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06855","EWH","161027","02611","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982786","title":"【直击ASCO 2026】亚盛医药MDM2-p53抑制剂APG-115儿童实体瘤数据首发，\"星光计划\"品种潜力初显","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982786","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640982786?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:40","pubTimestamp":1780278000,"startTime":"0","endTime":"0","summary":"此次快速口头报告的研究进展初步展现了APG-115在儿童相关实体瘤患者中的抗肿瘤活性和安全性。此次在ASCO 展示的数据证实，APG-115 单药及联合利沙托克拉展现出良好耐受性与显著抗肿瘤活性，尤其是CR 病例令人鼓舞。此次在ASCO展示的研究为APG-115治疗儿童实体瘤患者的数据首次亮相，初步展现的疗效和耐受性令人鼓舞。值得一提的是，APG-115此前已获CDE纳入'星光计划'，拟开发用于多种儿童实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4972105_ZH72105_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1923622291.USD","BK1161","06855","APG","BK1574","AAPG","BK4129","BK4139","LU2125909759.SGD","LU2125909916.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176445150","title":"异动解读｜亚盛医药-B盘中上涨6.35%，摘B里程碑叠加ASCO年会催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1176445150","media":"行情直击","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176445150?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:49","pubTimestamp":1780026583,"startTime":"0","endTime":"0","summary":"5月29日，亚盛医药-B盘中上涨6.35%，报39.86港元/股，成交额4217.63万港元。截至5月27日，公司市值约149.6亿港元，核心产品耐立克和利生妥收益超过5亿港元门槛。同时，ASCO年会于5月29日正式开幕，公司六项临床研究入选，其中三项获快速口头报告，涉及奥雷巴替尼、利沙托克拉及alrizomadlin三大重点品种。双重催化叠加生物科技板块整体回暖，信达生物涨10.29%、康方生物涨7.16%，带动公司股价走强。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639645908","title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2639645908","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639645908?lang=zh_cn&edition=full","pubTime":"2026-05-29 11:23","pubTimestamp":1780025014,"startTime":"0","endTime":"0","summary":"财报显示，2025年，亚盛医药实现营业收入5.74亿元，且截至目前市值已超过百亿港元。而耐立克和利生妥两大十亿美元分子相继获批上市并在终端市场实现快速放量，便是亚盛医药能够顺利达成18A“摘B”里程碑的重要原因。智通财经APP了解到，亚盛医药今年六项重磅研究成果入选2026年ASCO年会。以上无疑都将成为亚盛医药年内的重要催化。近年来已有10数家18A企业顺利“摘B”，并在“摘B”后实现了可观的估值增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447587.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"达成18A“摘B”里程碑叠加重磅成果再登ASCO，亚盛医药-B(06855)全球创新价值全面释放","news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AAPG","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638992766","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638992766","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638992766?lang=zh_cn&edition=full","pubTime":"2026-05-28 21:58","pubTimestamp":1779976713,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月28日，受托人就2022年受限制股份单位计划目的于场内购买合共5万股现有股份以在归属后满足受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","AAPG","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185669566","title":"异动解读｜亚盛医药-B盘中下跌6.24%，报37.58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185669566","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185669566?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:32","pubTimestamp":1779953535,"startTime":"0","endTime":"0","summary":"5月28日，亚盛医药-B盘中下跌6.24%，报37.58港元/股，成交额1.04亿港元。亚盛医药-B所在的生物科技行业整体承压，个股中，信达生物跌4.62%，康方生物跌4.34%，百济神州跌2.71%，三生制药跌7.23%，派格生物医药-B持平。亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司，核心产品包括耐立克（奥雷巴替尼）及Lisaftoclax（APG-2575），主要用于治疗CML、AML、CLL及MDS等血液肿瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651100","title":"亚盛医药获香港联交所批准从股票代码中移除\"B\"，6月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651100","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638651100?lang=zh_cn&edition=full","pubTime":"2026-05-28 11:06","pubTimestamp":1779937560,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2026年5月28日 /美通社/ --致力于在肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药宣布，因公司已符合香港联交所上市规则第8.05条的市值/收益要求，日前已获得香港联交所批准，将于2026年6月1日起正式将\"B\"标记从股票代码中移除。亚盛医药于2019年10月28日通过18A规则在香港联交所主板挂牌上市，后陆续纳入深港通和沪港通股票名单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4969934_ZH69934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","BK1574","BK1161","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638081685","title":"亚盛医药-B(06855)：受托人就2022年受限制股份单位计划购买合共10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2638081685","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638081685?lang=zh_cn&edition=full","pubTime":"2026-05-27 21:58","pubTimestamp":1779890296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，于2026年5月27日，受托人就2022年受限制股份单位计划目的于场内购买合共10万股现有股份以在归属后满足受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4139","BK1161","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638501850","title":"亚盛医药-B(06855)：中英文简称将不再加上标记“B”","url":"https://stock-news.laohu8.com/highlight/detail?id=2638501850","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638501850?lang=zh_cn&edition=full","pubTime":"2026-05-27 18:31","pubTimestamp":1779877916,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)发布公告，由于相关规则不适用，公司的中英文简称自2026年6月1日起将不再加上标记“B”。公司的股份将以新英文股份简称“ASCENTAGE”及中文股份简称“亚盛医药”在联交所买卖。公司的股份代号维持不变，仍为“6855”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","AAPG","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637363327","title":"亚盛医药-B(06855)：于2026年美国临床肿瘤学会年上公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637363327?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:46","pubTimestamp":1779407170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司六项入选2026年美国临床肿瘤学会年会的临床研究的摘要已于ASCO官网公布。本届ASCO年会将于2026年5月29日至2026年6月2日在芝加哥伊利诺伊州McCormick会议中心以线上线下结合的形式举办。该方案安全性可控，在儿童相关实体瘤中初步展现抗肿瘤活性，值得进一步研究。主要终点均为24周的主要分子学反应率。研究计划纳入约440例患者，在18个国家126个中心开展，目前正在招募中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1574","BK1161","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134177422","title":"异动解读｜亚盛医药盘中上涨7.32%，股东大会释放积极信号叠加指南纳入利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134177422","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134177422?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:05","pubTimestamp":1779329125,"startTime":"0","endTime":"0","summary":"5月21日，亚盛医药-B盘中上涨7.32%，报41.8港元/股，成交额5379.54万港元。消息面上，公司5月20日召开股东大会，管理层释放多重积极信号：明确核心产品APG-2575将立足自主商业化、不对外出售，已在寻找美国首席商务官；强调与武田的合作\"没有问题\"；并表示MDS适应症为最高优先级临床项目，计划明年下半年申请快速通道资格。此外，公司Bcl-2抑制剂利沙托克拉近日获纳入CSCO两项诊疗指南，在CLL/SLL、AML及MDS领域获权威推荐。多重利好共振推动股价反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0561508036.HKD","LU0348767384.USD","LU0348784397.USD","IE00B543WZ88.USD","00460","LU0417516571.SGD","LU2399975544.HKD","LU1794554557.SGD","LU0348783233.USD","LU0417516738.SGD","LU2328871848.SGD","159938","BK1587","LU2488822045.USD","01672","BK1574","IE00BPRC5H50.USD","BK1600","LU0348766576.USD","BK1515","LU2476274308.USD","LU2778985437.USD","LU0417516902.SGD","BK1583","159992","02410","BK1161","LU0348735423.USD","06978","09926","LU2476274720.SGD","02268","LU1720050803.USD","LU0634319403.HKD","09939","02162","LU0540923850.HKD","LU1969619763.USD","06855","BK1191","BK1141","LU0348825331.USD","SG9999014674.SGD","BK1593","IE00B5MMRT66.SGD","09995","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163156926","title":"亚盛医药-B发布4月股份变动月报表，股本小幅增长10,058股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163156926","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163156926?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:43","pubTimestamp":1778164980,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年5月7日发布2026年4月股份变动月报表。公告显示，该公司截至2026年4月30日的法定/注册股本维持500,000,000股普通股，面值每股0.0001美元，对应注册股本共计50,000美元，未产生任何增减变动。公告披露，4月末已发行股份总数为373,334,750股，较3月底增加10,058股，库存股份数量保持为0股。截至4月底，亚盛医药-B股本结构整体保持相对稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.1193},{"period":"1month","weight":-0.0412},{"period":"3month","weight":-0.3295},{"period":"6month","weight":-0.3143},{"period":"1year","weight":-0.5531},{"period":"ytd","weight":-0.3321}],"compareEarnings":[{"period":"1week","weight":-0.0009},{"period":"1month","weight":-0.1146},{"period":"3month","weight":-0.0821},{"period":"6month","weight":-0.1247},{"period":"1year","weight":-0.0482},{"period":"ytd","weight":-0.1005}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.714286,"avgChangeRate":0.098263},{"month":5,"riseRate":0.428571,"avgChangeRate":0.029409},{"month":6,"riseRate":0.714286,"avgChangeRate":0.240354},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.058707},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药","nameEN":"ASCENTAGE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,06855,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}